Development and clinical evaluation of Prevnar 13, a 13-valent pneumocococcal CRM197 conjugate vaccine

The development of 13-valent pneumococcal conjugate vaccine and its possible use in adults

(2011) Robert W Frenck et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine in Children Previously Immunized With 7-valent Pneumococcal Conjugate Vaccine

(2011) Robert Frenck et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given With Routine Pediatric Vaccinations in Canada

(2011) Otto G. Vanderkooi et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Immunogenicity of a combination vaccine containing diphtheria toxoid, tetanus toxoid, three-component acellular pertussis, hepatitis B, inactivated polio virus, and Haemophilus influenzae type b when given concomitantly with 13-valent pneumococcal conjugate vaccine

(2011) Francisco Gimenez-Sanchez et al.   VACCINE

Phase 3 trial evaluating the immunogenicity, safety, and tolerability of manufacturing scale 13-valent pneumococcal conjugate vaccine

(2011) Janusz Gadzinowski et al.   VACCINE

The 13-valent pneumococcal conjugate vaccine (PCV13) elicits cross-functional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A

(2011) David Cooper et al.   VACCINE

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine (PCV13) when given as a toddler dose to children immunized with PCV7 as infants

(2011) E. Grimprel et al.   VACCINE

Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

(2011) Elizabeth Miller et al.   VACCINE

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Compared to Those of a 7-Valent Pneumococcal Conjugate Vaccine Given as a Three-Dose Series with Routine Vaccines in Healthy Infants and Toddlers

(2010) S. Esposito et al.   Clinical and Vaccine Immunology

Association of Serotype with Risk of Death Due to Pneumococcal Pneumonia: A Meta‐Analysis

(2010) Daniel M. Weinberger et al.   CLINICAL INFECTIOUS DISEASES

Invasive Pneumococcal Disease in Alaskan Children

(2010) Jay D. Wenger et al.   PEDIATRIC INFECTIOUS DISEASE JOURNAL

Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine

(2010) K. A. Bryant et al.   PEDIATRICS

Serotype 19A Is the Most Common Serotype Causing Invasive Pneumococcal Infections in Children

(2010) S. L. Kaplan et al.   PEDIATRICS

Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in Infants and Toddlers

(2010) S. H. Yeh et al.   PEDIATRICS

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

(2010) Dorothee M. Kieninger et al.   VACCINE

Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine

(2009) Tamara Pilishvili et al.   JOURNAL OF INFECTIOUS DISEASES

Challenges in the evaluation and licensing of new pneumococcal vaccines, 7–8 July 2008, Ottawa, Canada

(2009) I. Feavers et al.   VACCINE

Pneumococcal Necrotizing Pneumonia in Utah: Does Serotype Matter?

(2008) Jeffrey M. Bender et al.   CLINICAL INFECTIOUS DISEASES

Trends in Acute Otitis Media-Related Health Care Utilization by Privately Insured Young Children in the United States, 1997-2004

(2008) F. Zhou et al.   PEDIATRICS

Impact of the introduction of pneumococcal conjugate vaccine on rates of community acquired pneumonia in children and adults

(2008) Jennifer C. Nelson et al.   VACCINE